No CrossRef data available.
Article contents
Serious Adverse Events and the Modafinil Augmentation Study
Published online by Cambridge University Press: 07 November 2014
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
- Type
- Letter to the Editor
- Information
- Copyright
- Copyright © Cambridge University Press 2006
References
REFERENCES
1.Thase, ME, Fava, M, DeBattista, C, Arora, S, Hughes, RJ. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr. 2006;11(2):93–102.Google Scholar
1.Fava, M, Thase, ME, DeBattista, C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005;66:85–93.Google Scholar
2.Khan, A, Khan, S, Kolts, R, Brown, WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: Analysis of FDA reports. Am J Psychiatry. 2003;160:790–792.CrossRefGoogle ScholarPubMed
3.Ferguson, D, Doucette, S, Glass, KC, et al.Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomized controlled trials. BMJ. 2005;330:396–402.Google Scholar
4.Gunnell, D, Saperia, J, Ashby, D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo-controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ. 2005;330:385.CrossRefGoogle Scholar
5.FDA Public Health Advisory. Suicidality in adults being treated with antidepressant medications. Available at: http://www.fda.gov/cder/drug/advisory/SSRI200507.htm. June 30. 2005. Accessed March 17, 2006.Google Scholar
You have
Access